Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Southern Medical University, China | OTHER |
Not provided
Not provided
Not provided
To focus on the real world treat-to-target rate of early rheumatoid arthritis patients who will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA.
To explore the factors which influence the treat-to-target outcome.
Resent study showed that rapid progression of cartilage and bone damage could happen on the early state of RA patients, so the clinicians should try the best to stop the trend, such as early diagnosis, early treatment and treat-to-target. But only half of the RA patients could reach low disease activity in the whole world and about 10% in China.
The investigators enroll early RA patients who are treated according to the 2015 American College of Rheumatology Guideline. The relevant data are collected and analyzed by the statistician including clinical data, imaging markers, blood samples and patient-reported outcomes every 3 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| early RA patients | patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months. If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| disease modified antirheumatic drugs or biological agents | Drug | Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA |
| Measure | Description | Time Frame |
|---|---|---|
| the proportion of patients achieving treat to target | calculate the proportion of patients achieving treat to target according to the change of DAS28 score | 2018-4-25 to 2022-7-1 |
| Measure | Description | Time Frame |
|---|---|---|
| the change of Health Assessment Questionnaire Disability Index(HAQ-DI) | the change of Health Assessment Questionnaire Disability Index(HAQ-DI) | 2018-4-25 to 2022-7-1 |
| the change of The Work Productivity and Activity Impairment Questionnaire(WPAI) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants entering this study are recruited from two hospital sites: Nanfang Hospital, Southern Medical University and Zhujiang Hospital, Southern Medical University.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Min Yang, doctor | Contact | +86-13802911770 | minyanggz@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Min Yang, doctor | Nanfang Hospital, Southern Medical University | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30446575 | Derived | Zhao J, Zhan T, Zhu J, Fan M, Huang Q, Ren H, Wu J, Yu Q, Lin J, Ouyang Q, An S, Yang M. Long-term prognosis and quality of life in patients with early rheumatoid arthritis treated according to the 2015 ACR guideline (LELAND): protocol for a multicentre prospective observational study in Southern China. BMJ Open. 2018 Nov 15;8(11):e023798. doi: 10.1136/bmjopen-2018-023798. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001685 | Biological Factors |
| D018501 | Antirheumatic Agents |
| D001688 | Biological Products |
| ID | Term |
|---|---|
| D045506 | Therapeutic Uses |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
|
the change of The Work Productivity and Activity Impairment Questionnaire(WPAI)
| 2018-4-25 to 2022-7-1 |
| the change of European Quality of Life-5 Dimensions(EQ-5D) | the change of European Quality of Life-5 Dimensions(EQ-5D) | 2018-4-25 to 2022-7-1 |
| the change of Short Form 36 Health Survey Questionnaire(SF-36) | the change of Short Form 36 Health Survey Questionnaire(SF-36) | 2018-4-25 to 2022-7-1 |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |